{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:32:11Z","timestamp":1778038331753,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.ejca.2004.07.035","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T12:23:58Z","timestamp":1100262238000},"page":"346-356","source":"Crossref","is-referenced-by-count":63,"title":["Endocrine treatment options for advanced breast cancer \u2013 the role of fulvestrant"],"prefix":"10.1016","volume":"41","author":[{"given":"J.F.R.","family":"Robertson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.E.","family":"Come","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Beex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Makris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.R.","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Possinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.-E.","family":"Rutqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2004.07.035_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","article-title":"Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels","volume":"12","author":"Bertelli","year":"1988","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2004.07.035_bib4","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib5","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib6","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib7","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib8","first-page":"29A","article-title":"Efficacy and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European phase II trial with Pharmacia and Upjohn","volume":"20","author":"Dirix","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00662401","article-title":"Toremifene and tamoxifen in advanced breast cancer \u2013 a double-blind cross-over trial","volume":"25","author":"Stenbygaard","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.1993.11.2.345","article-title":"Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer","volume":"11","author":"Vogel","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00666475","article-title":"High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment","volume":"29","author":"Pyrhonen","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1997.375","article-title":"Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the \u2018Nordic\u2019 Phase III study","volume":"76","author":"Pyrhonen","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2004.07.035_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1006250213357","article-title":"Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of anti-oestrogen therapy in postmenopausal women with breast cancer","volume":"56","author":"Pyrhonen","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib14","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1200\/JCO.2000.18.20.3487","article-title":"Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group","volume":"18","author":"Holli","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/02841869209088284","article-title":"Droloxifene \u2013 a new anti-estrogen. A phase II study in advanced breast cancer","volume":"31","author":"Haarstad","year":"1992","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00685906","article-title":"Phase I trial of droloxifene in patients with metastatic breast cancer","volume":"33","author":"Buzdar","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2004.07.035_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015229630260","article-title":"Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER\/PgR-positive advanced breast cancer","volume":"73","author":"Buzdar","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib18","first-page":"1070","article-title":"Idoxifene: a report of a phase I study in patients with metastatic breast cancer","volume":"55","author":"Coombes","year":"1995","journal-title":"Cancer Res"},{"issue":"Suppl 12","key":"10.1016\/j.ejca.2004.07.035_bib19","first-page":"4376S","article-title":"Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies","volume":"7","author":"Johnston","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2003.06.108","article-title":"Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer","volume":"21","author":"Buzdar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000226637","article-title":"Phase II evaluation of Ly156758 in metastatic breast cancer","volume":"45","author":"Buzdar","year":"1988","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2004.07.035_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2001.tb04011.x","article-title":"The MORE trial: multiple outcomes for raloxifene evaluation \u2013 breast cancer as a secondary end point: implications for prevention","volume":"949","author":"Dickler","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2004.07.035_bib24","first-page":"602","article-title":"The STAR (study of tamoxifen and raloxifene) trial in West Virginia","volume":"96","author":"Jubelirer","year":"2000","journal-title":"W V Med J"},{"key":"10.1016\/j.ejca.2004.07.035_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/bcr436","article-title":"Estrogen as therapy for breast cancer","volume":"4","author":"Ingle","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1006185805079","article-title":"Randomized trial of diethylstilbestrol versus tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis","volume":"54","author":"Peethambaram","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"L\u00f8nning","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.2910550529","article-title":"Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780","volume":"55","author":"Hu","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2004.07.035_bib29","first-page":"408","article-title":"Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer","volume":"54","author":"DeFriend","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00685924","article-title":"The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth","volume":"34","author":"Osborne","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 12","key":"10.1016\/j.ejca.2004.07.035_bib31","first-page":"4369s","article-title":"Preliminary experience with pure antiestrogens","volume":"7","author":"Howell","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1749-6632.1995.tb31376.x","article-title":"Responses to pure anti-oestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer","volume":"761","author":"Nicholson","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2004.07.035_bib33","first-page":"2321","article-title":"Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines","volume":"56","author":"Pink","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib34","first-page":"557","article-title":"The novel ER down-regulator, Faslodex, modulates EGFR\/MAPK activity in tamoxifen-resistant MCF-7 breast cancer cells","volume":"7","author":"Hutcheson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1025484908380","article-title":"Oestrogen receptor-mediated modulation of the EGFR\/MAPK signalling pathway in tamoxifen-resistant MCF-7 breast cancer cells","volume":"81","author":"Hutcheson","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib36","first-page":"6739","article-title":"Comparison of the short-term biological effects of 7\u03b1-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17\u03b2-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer","volume":"61","author":"Robertson","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib37","first-page":"2317","article-title":"Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen","volume":"22","author":"Bundred","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2004.07.035_bib38","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American Trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib39","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials","volume":"98","author":"Robertson","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2004.07.035_bib41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0959-8049(03)00199-0","article-title":"Fulvestrant (FaslodexTM) versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials","volume":"39","author":"Mauriac","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2004.07.035_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1023983032625","article-title":"Postmenopausal women who progress on fulvestrant (\u2018Faslodex\u2019) remain sensitive to further endocrine therapy","volume":"79","author":"Vergote","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2004.07.035_bib43","first-page":"46","article-title":"Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women","volume":"13","author":"Robertson","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2004.07.035_bib44","first-page":"S72","article-title":"Postmenopausal women with advanced breast cancer who progress on Fulvestrant or tamoxifen retain sensitivity to further endocrine therapies","volume":"76","author":"Howell","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2307\/3464849","article-title":"Back to basics. Administering i.m. injections the right way","volume":"96","author":"Beyea","year":"1996","journal-title":"Am J Nurs"},{"key":"10.1016\/j.ejca.2004.07.035_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00280-003-0643-7","article-title":"Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (\u2018Faslodex\u2019) in postmenopausal women with advanced breast cancer","volume":"52","author":"Robertson","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2004.07.035_bib47","doi-asserted-by":"crossref","unstructured":"The ATAC Trialists\u2019 Group. Arimidex, tamoxifen alone or in combination. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131\u201339","DOI":"10.1016\/S0140-6736(02)09088-8"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2004.07.035_bib48","first-page":"S72","article-title":"Fulvestrant (\u2018Faslodex\u2019) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors","volume":"76","author":"Perey","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2004.07.035_bib49","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","article-title":"Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial","volume":"18","author":"L\u00f8nning","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib50","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results if a Phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib51","first-page":"60A","article-title":"Sequential use of aromatase inactivators and inhibitors in advanced breast cancer","volume":"21","author":"Bertelli","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2004.07.035_bib52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bjc.1994.281","article-title":"Effects of 4-hydroxytamoxifen and a novel pure anti-oestrogen (ICI 182870) on the clonogeneic growth of human breast cancer cells in vitro","volume":"70","author":"DeFriend","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2004.07.035_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1677\/erc.0.0080175","article-title":"Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer","volume":"8","author":"Nicholson","year":"2001","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 12","key":"10.1016\/j.ejca.2004.07.035_bib54","first-page":"4350S","article-title":"Prospects for combining hormonal and non-hormonal growth factor inhibition","volume":"1","author":"Wakeling","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904007518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904007518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T23:21:13Z","timestamp":1549063273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904007518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0959804904007518"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.07.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}